CBEH research updates: January 2018

8 Feb 2018

Exploring the economic importance of women's health

Professor Brenda Gannon has been invited to speak at the inaugural National Women’s Health Summit,  hosted by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) in Sydney on Friday 2 March 2018.

Professor Gannon will speak on the economic importance of women’s healthThe full program is also available download here

Ahead of the next Federal election, the group aims to identify the key policy gaps that need to be addressed by Australian Governments at all levels over the next ten years. 

International Linkage with the University of Bologna

In October 2017, Professor Luke Connelly accepted a part-time appointment at The University of Bologna (est. 1088) that was offered via the Direct Call appointment process. With colleagues at The University of Bologna, he is conducting research on a number of important questions in health economics, including the effect of policy changes on the incentives faced by medical practitioners and the resulting effects on behaviour, the consumption of health care services, and health outcomes.

This link builds upon CBEH’s existing linkages in the UK, Europe and the United States.

Professor Connelly’s University of Bologna profile can be viewed here.

Cost-Effectiveness Analysis of Genetic Testing

Professor Luke Connelly’s work with colleagues from Griffith University, The University of Queensland and the Department of Human Services on genetic testing in breast and ovarian cancer has been published in the Nature journal Genetics in Medicine. The article examines the effectiveness and cost-effectiveness of testing women who are diagnosed with breast cancer for the BRCA1 and BRCA2 genetic mutations, as well as their first-degree relatives (e.g., daughters, siblings) when a mutation is found. BRCA mutation carriers have an elevated risk of breast and ovarian cancer. The information that genetic testing can provide to the relatives of women with a BRCA-positive test result may help them to make important life choices such as when to have children and whether clinical interventions, such as more frequent screening or mastectomy and oophorectomy procedures should be considered.

Pregabalin versus Placebo to Prevent Chronic Whiplash

With colleagues from Australia and the United States, Professor Luke Connelly has contributed to a study protocol has been published on the use of pregabalin (versus placebo) to target pro-nociceptive mechanisms in patients who are at-risk of chronic whiplash. The paper, published in Trials, describes the feasibility of trial procedures to collect effectiveness data with a view to establishing the effectiveness and cost-effectiveness.

Reducing Medical Admissions to Hospital by Optimising Medicine Use

Professor Luke Connelly is part of a team, led by researchers at the UQ School of Pharmacy, that is investigating the effectiveness and cost-effectiveness of medicine review to prevent hospitalisations that may be caused when people take inappropriate or sub-optimal combinations of medicines. The protocol for this study, which uses a stepped-wedge randomised controlled trial design, has been published in BMJ Open.

National Health and Medical Research Council (NHMRC) Grant Success

Professor Luke Connelly is a Chief Investigator on the NHMRC Project Grant Implementation of a Novel Clinical Pathway of Care for Common Musculoskeletal Disorders in Primary Care, which is led by Dr Trudy Rebbeck (University of Sydney). The team, which includes researchers from UQ’s Recover Injury Research Centre (Professor Michele Sterling), The University of Sydney, and The University of New South Wales was awarded more than $1.5m over five years for a project to conduct a multi-centre study of the implementation of a novel clinical pathway of care for common musculoskeletal disorders in primary care.

Professor Brenda Gannon is a Chief Investigator on an NHMRC Project Grant led by A/Prof Andreas Schibler, Mater Research Institute –UQ and Lady Cilento Children’s Hospital, Emergency Care, Paediatric Intensive Care Unit. The project, Nasal Highflow (NHF) for Paediatric Acute Hypoxic Respiratory Failure, (AHRF) will investigate in an RCT performed in children aged 1-4, presenting with acute hypoxemic respiratory failure, if the early use of NHF therapy is superior to standard oxygen therapy with a reduced intensive care admission rate.  Professor Gannon will lead the economic analysis to see if treatment is cost-effective and reduce the health costs among children with AHRF.  The project runs from 2018-2021 and was awarded $2,627, 819.

Dr Jonas Fooken is an Associate Investigator on another Mater Research Institute-UQ project, also led by A/Prof Andreas Schibler. He will conduct an economic evaluation on resource use and cost data in the project Nitric Oxide on Cardio Pulmonary Bypass in Congenital Heart Disease , and Professor Gannon will assist in supervision. The project runs from 2018-2021 and was awarded $1,878,889.